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OBJECTIVE—The study objectives were 1) to assess the effectiveness and safety of a stan-
dardized protocol for the transition to subcutaneous insulin and oral feeding in diabetic or
hyperglycemic patients with acute coronary syndrome (ACS) who were receiving intravenous
insulin and glucose at the time of the transfer from the intensive cardiac care unit to a general
ward and 2) to identify predictors of transition outcome.
RESEARCH DESIGN AND METHODS—This was a prospective observational study.
The protocol speciﬁes that patients receive a 100% of their daily subcutaneous insulin require-
ment from the ﬁrst day of oral feeding, calculated from the intravenous insulin rate during the
ﬁnal 12 h divided into two: 50% basal and 50% prandial.
RESULTS—In 142 patients (93 male, 49 female, age range 47–88 years, 135 with known
diabetes) the ﬁrst day after transition, 44.8% of blood glucose (BG) measurements were within
thestrictrangeof100–140mg/dLbeforemealsand100–180mg/dLaftermeals,and70.8%were
within the broader ranges of 80–160 mg/dL and 80–200 mg/dL, respectively. Pre- or postpran-
dial hypoglycemia (BG ,70 mg/dL) occurred in 11 patients (7.7%) on the ﬁrst day and in 38
patients (26.8%) on the ﬁrst 3 days after transition. Old age, high doses of intravenous insulin,
and wide BG variations in the 24 h before insulin infusion was stopped were predictive of poor
BG control after transition.
CONCLUSIONS—This study shows the effectiveness and safety of a standardized protocol
for the transition from intravenous to subcutaneous insulin in patients with ACS when regular
oral feeding was resumed.
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I
n critically ill patients with diabetes or
hyperglycemia who are admitted to
intensive care units, intravenous in-
fusion of insulin is the recommended
treatment (1–6). During the postacute
phase, many guidelines and recommen-
dations suggest switching to subcutane-
ous insulin when patients begin eating
regular meals and are moved to a lower-
intensity care setting (1–6).
There are few observational and in-
tervention studies on the procedure for
the transition from intravenous to subcu-
taneous insulin, and almost all concerned
patientswhohadundergoneoperationand
tooklittleifanyfood(7–11).Thetransition
is delicate because of the patients’ clinical
condition and the organizational context
in which they are transferred from an in-
tensive care unit to a general ward. The
fewstudiesthathaveexaminedthecourse
of blood glucose (BG) after interruption
of intravenous insulin have documented
inadequate control in the absence of a
standardized transition protocol (9,12).
In addition, the literature reporting the
predictors of optimal transition is scarce
and refers mainly to patients postsurgery
(7,9,10).
T h eo b j e c t i v e so ft h i sp r o s p e c t i v e
observational study were to
1) assess the effectiveness and safety of a
standardized protocol for conversion
from intravenous to subcutaneous in-
sulin therapy in patients with acute
coronary syndrome (ACS) during the
transfer from the intensive cardiac care
unit (ICCU) to the general ward; and




Desio Diabetes Diagram transition
protocol
The Desio Diabetes Diagram (DDD) tran-
sition protocol is part of a more compre-
hensive original protocol (Organization
and optimization of Care in Team to
improve Outcomes in Patients with hy-
perglycemia admitted to coronary care
Unit/cardiology division for acute coro-
nary Syndromes [OCTOPUS]) for the full
acute and subacute metabolic manage-
ment of patients with diabetes or hyper-
glycemia admitted to the Ospedale di
Desio ICCU for suspected ACS. The pro-
tocol is the outcome of collaboration
between the cardiologist responsible for
the ICCU (FA) and the diabetologist re-
sponsible for the Diabetes and Metabolic
DiseasesUnit(GM).Thename“OCTOPUS”
reﬂects the multiple therapeutic approaches
(intravenous insulin infusion at ﬁrst, fol-
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ORIGINAL ARTICLEglucose during the acute phase, followed by
oral carbohydrates) and the several health
teamsinvolved(medical,nursing,andsup-
portpersonneloftheICCUandCardiology
Department; physicians, nurses, and dieti-
tiansofthe Diabetesand MetabolicDisease
Unit) (13).
The OCTOPUS project adopted the
nurse-implemented DDD insulin infu-
sion protocol for intensive glycemic con-
trol during the acute phase, with target
BG between 100 and 139 mg/dL (13).
At admission to the ICCU, each di-
abetic patient received glucose solution
by infusion, parallel with, but separately
from,theintravenousinsulintoguarantee
the necessary carbohydrate supply, as
suggested by recent nutritional recom-
mendations (4,14). The glucose dose was
calculated on the basis of the estimated
amount of carbohydrate needed in the
diet for the postacute phase, to supply
20 Kcal per kilogram of ideal weight (of
which ;60% are carbohydrates), taking
into account the 10% lower bioavailabil-
ityoftheoralroute.Toguaranteethe24-h
glucose intravenous intake, glucose con-
centrations and infusion rates varied in
relation to the patient’s clinical condition
and the availability of venous access (13).
The conversion from intravenous in-
fusion to subcutaneous insulin was
scheduled when most of the BG measure-
ments remained within the target range
for at least 24 h. Table 1 reports the DDD
protocol for conversion.
Every 1–2 days the subcutaneous
glargine and lispro insulin scheduled
dosesweretitrated,increasingordecreas-
ing the previous dose by 10–20% de-
pending on pre- and postprandial BG,
respectively (BG preprandial target
,120 mg/dL and postprandial target
,160 mg/dL). If pre- or postprandial hy-
perglycemia occurred, a correction dose
of subcutaneous insulin lispro was ad-
ministered according to an algorithm
that takes into account the total daily
dose of insulin (15).
The conversion to subcutaneous in-
sulin was started the day of the ﬁrst
evening meal, giving the ﬁrst dose of
insulin glargine 2 hours before dinner.
Immediately before dinner, intravenous
insulinandglucosewerestopped,andthe
ﬁrst dose of insulin lispro was given. On
thenextday,theinsulinglargineinjection
was given at lunch.
Training
Before starting the DDD insulin infusion
and transition from the intravenous to
subcutaneous protocols, all nurses and
physicians attended a 2–3-h training
meeting on the use of protocols. Some
months from the start of application of
the protocols, then yearly, further meet-
ings were held with the whole staff to as-
sess the results, discuss problems, and
decide on solutions.
Patients
All patients consecutively admitted to the
Ospedale di Desio ICCU from May 2006
to May 2008 for suspected ACS and
known diabetes, or with BG .200 mg/dL,
were treated with the DDD insulin infu-
sion protocol. Those whose BG remained
withinthe target interval(100–139) inthe
last24hwith,0.5units/hofinsulin,thus
with estimated daily insulin needs ,12
units, were excluded and did not shift to
subcutaneous insulin.
Measurements
BG was measured in venous blood every
1–2hduringintravenousinsulininfusion
and in capillary blood before and 2 h after
each meal during subcutaneous insulin
using a bedside glucometer (Ascensia
Elite XL, Bayer, Tarrytown, NY).
Outcomes
The primary outcome was the percentage
of BG in the range of 100–140 mg/dL be-
fore meals and 100–180 mg/dL after
meals (2–4) on the ﬁrst day after transi-
tion. Secondary outcomes were the per-
centage of BG in the wider range of
80–160 mg/dL before meals and 80–200
mg/dL after meals on the ﬁrst day after
transition; the percentage of hypoglyce-
mia (deﬁn e di nt h i ss t u d ya sB G,70
mg/dL) the ﬁrst day after transition; the
percentage of BG in the tighter and wider
ranges before and after meals on the sec-
ond and third days after transition; the
percentage of hypoglycemia on the sec-
ond and third days after transition; and
deathsinhospitalandmainnonlethalcar-
diovascular complications (myocardial
reinfarction, heart failure, ventricular ﬁ-




subcutaneous insulin and oral diet
An estimate of the combined basal and nutritional subcutaneous insulin requirements can be
extrapolated from the average amount of intravenous insulin infused during the hours
preceding the conversion if:
1) the intravenous glucose infusion is kept constant and equivalent to the amount of
carbohydrate in the oral diet and
2) the BG level is stable in the target range between 100 and 139 mg/dL (most of the BG
measurements on target for at least 24 h)
Protocol Example
Step 1. Calculate the average insulin
Ć intravenous infusion rate in the last 12 h
Ć to obtain the mean hourly rate and
Ć multiply by 24 to get the total daily
Ć insulin requirement.
→ 1.5 units/h 3 24 = 36 units/24 h
Step 2. Halve this 24-h insulin dose to obtain
Ć the long-acting insulin analog dose and
Ć total daily rapid-acting insulin analog
Ć dose.
→ 36 units/2 = 18 units
Step 3. Give the long-acting insulin analog
Ć subcutaneous monodose 2 h before the
Ć ﬁrst meal and the discontinuation of
Ć intravenous insulin and intravenous
Ć glucose infusions.
→ give glargine 18 units s.c. 2 h before the ﬁrst
meal and stop intravenous insulin and glucose
infusions at meal
Step 4. Split the total daily rapid-acting
Ć subcutaneous insulin analog dose into
Ć 20% at breakfast, 40% at lunch, and
Ć 40% at dinner, according to a similar
Ć distribution of carbohydrates in the
Ć typical Mediterranean diet.
→ give lispro 4 units s.c. before breakfast, give
lispro 7 units s.c. before lunch, give lispro 7
units s.c. before dinner
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Intravenous to subcutaneous insulinStatistical analysis
Quantitative variables were described us-
ing mean 6 SD if normally distributed.
When this condition was not satisﬁed
the median was used instead of the
mean, and the ﬁrst and third quartiles
were used to obtain a CI (25th –75th per-
centile). Qualitative variables are ex-
pressed as percentages.
We used a stepwise logistic multivar-
iate analysis to identify the variables
associatedwithanunsuccessfultransition
to subcutaneous insulin (patients with
,50% of BG in the range of 100–140
mg/dL before meals and 100–180 after
meals on the ﬁrst day after transition from
intravenoustosubcutaneousinsulin)(2–4).
Selected variables of clinical interest in-
cluded in the model were sex, age, BMI,
smoking habit, history of hypertension,
hypercholesterolemia and diabetes, dura-
tion of diabetes, previous insulin treat-
ment, reason for hospitalization (ST
elevation myocardial infarction vs. other),
BGandHbA1catadmission,mean BGand
mean intravenous insulin dose adminis-
tered in the last 12 and 24 h, and the total
dose of subcutaneous insulin given the
ﬁrst day after transition. Selected indexes
of variability in BG and insulin doses dur-
ing the last 12 and 24 h of intravenous
insulin included in the model were SD,
coefﬁcient of variation (SD/mean) and
trend (difference of mean values in ﬁrst
and second half of the interval) for BG
and insulin dose, percentage of BG at tar-
get, and mean amplitude of the glycemic
excursion (MAGE) (16). The MAGE (16)
was calculated by measuring the arithme-
ticmeanofthedifferencebetweenconsec-
utive peaks and nadirs, provided that the
difference was greater than the SD around
the BG mean. All the quantitative covari-
ates analyzed were introduced in the
model in categories (higher and lower
than the median). The results of multivar-
iate analysis are reported as odds ratio
(OR) with 95% CI.
RESULTS—In the ﬁrst 2 years of appli-
cation of the OCTOPUS protocol, 172
patients (60 women, 112 men), with a
mean age of 69.8 6 10.7years(range42–
90 years), were treated with intravenous
insulin infusion. The transition from intra-
venous to subcutaneous insulin involved
145 patients (84.3%): in 27 patients, the
transitionwasnotdonebecausetheinsulin
infusionprotocolwasstoppedprematurely
(2 patients died, 11 patients had to be
transferred to other hospitals or wards,
otherreasonsin2patients)orthetransition
was not considered necessary because BG
wasatthetargetwithlowinsulindoses(12
patients). Among the 145 patients who
were shifted from intravenous to subcuta-
neous insulin, 3 (2.1%) were excluded
fromtheanalysisbecausesubcutaneousin-




Table 2 shows the main details of the
142 patients in the study. In all, 135 pa-
tients (95.1%) were known to have dia-
betes and 92 patients (64.8%) had BG
.200 mg/dL at admission. At discharge,
the diagnosis of ACS was conﬁrmed in
118 patients (83.1%), ST-segment eleva-
tion acute myocardial infarction was
conﬁrmed in 38 patients (26.8%), non–
ST-segment elevation acute myocardial in-
farction was conﬁrmed in 69 patients
(48.6%), and unstable angina was con-
ﬁrmed in 11 patients (7.7%). During a me-
dianhospitalstayof10days(7–14,25–75th
percentiles of median), there were 3 deaths
due to cardiogenic shock and 15 major
nonlethal cardiovascular complications
in 14 patients (3 myocardial reinfarctions,
2 ventricular ﬁbrillations, 2 sustained
ventricular tachycardias, 7 heart failures,
and 1 ischemic stroke).
Effectiveness of the protocol
Figure 1 shows the mean 6 SD of BG in
the last 24-h infusion, 2 hours after the
ﬁrst dinner, and before and 2 hours after
breakfast, lunch, and dinner on the ﬁrst 3
days after the transition from intravenous
to subcutaneous insulin.
On the ﬁrst day after shifting from
intravenous insulin, 826 BG measure-
ments were performed, 423 preprandial
and403postprandialofthe852measure-
ments scheduled (96.9%), with an aver-
age of 5.8 BG measurements per patient.
Of the 423 preprandial BG values, 164
(38.8%) were 100–140 mg/dL and 302
(71.4%) were 80–160 mg/dL; of the 403
postprandial BG values, 206 (51.1%)
were 100–180 mg/dL and 283 (70.2%)
were 80–200 mg/dL.
On the second day of subcutaneous
insulin, 39.3 and 67.2% of BG measure-
ments before meals (159 and 272/405)
were in the ranges of 100–140 and
80–160 mg/dL, respectively, and 51.4
and 68.6% of BG measurements after
meals (198 and 264 of 385) were in the
Table 2—Main characteristics of the population (142 patients)
Age (years)
Mean 6 SD 69.8 6 10.1
Range 47–88
Male (n, %) 93 (65.4%)
History of diabetes before hospital admission (n,% )
None 7 (4.9%)
Type 1 diabetes 3 (2.1%)
Type 2 diabetes 130 (91.6%)
Other types 2 (1.4%)




Insulin and oral drugs 5 (3.5%)
BMI (kg/m
2,m e a n6 SD) 28.2 6 4.4
Glycated hemoglobin (%, mean 6 SD) 7.7 6 1.6
BG (mg/dL, mean 6 SD)
At hospital admission 248.1 6 99.6
At the end of the insulin infusion 110.1 6 20.3
Insulin infusion (median, 25th–75th percentile of median)
Duration (h) 51 (45–70)
Hourly insulin dose at the end of the infusion (units) 1.5 (1.1–2.2)
Subcutaneous insulin (median, 25th–75th percentile of median)
Total daily insulin dose the ﬁrst day (units) 36 (24–52)
Total daily insulin dose the second day (units) 40 (26–56)
Total daily insulin dose the third day (units) 40 (26–59)
Carbohydrate intake (g/day, mean 6 SD)
Glucose intravenous in the last 24 h of insulin infusion 166.8 6 9.9
Oral intake of carbohydrates in the ﬁrst day after transition 185.6 6 13.2
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Avanzini and Associatesranges of 100–180 and 80–200 mg/dL,
respectively.
On thethirdday,therewere 38.8and
70.1% of preprandial BG measurements
within the range of 100–140 and 80–160
mg/dL(148and267of381)and52.8and
67.2% of postprandial BG within the
ranges of 100–180 and 80–200 mg/dL
(195 and 248 of 369), respectively.
Safety of the protocol
Pre- or postprandial hypoglycemia (BG
,70 mg/dL) was observed in 11 patients
(7.7%) on the ﬁrst day after transition
from intravenous to subcutaneous insu-
lin, in 21 patients (14.8%) on the second
day, and in 20 patients (14.1%) on the
third day. Overall, 38 patients (26.8%)
presentedatleastoneepisodeofhypogly-
cemia in the ﬁrst 3 days after transition.
BG was ,70 mg/dL 13 times on the
ﬁrst day (2.8% of BG measured before
meals and 0.2% of BG measured after
meals), 25 times on the second day
(3.7% of pre- and 2.6% of postprandial
BG measurements), and 23 times on the
third day (3.7% of pre- and 2.4% of post-
prandial BG measurements).
Of all the 61 hypoglycemic episodes
intheﬁrst3daysaftertransition,2(3.3%)
were ,40 mg/dL, 3 (4.9%) were 40–49
mg/dL, 11 (18.0%) were 50–59 mg/dL,
and the majority (45, 73.8%) were 60–
69 mg/dL.
All hypoglycemic episodes were
asymptomatic, with no manifest clinical
consequences. Among the 38 patients
with hypoglycemic episodes during the
ﬁrst3daysaftertransitiontosubcutaneous
insulin, there was one death (2.6%)
and six major nonlethal cardiovascular
complications (15.8%). The correspond-
ing ﬁg u r e sf o r1 0 4p a t i e n t sw i t h o u th y -
poglycemic events were 2 (1.9%) and 9
(7.7%).
Predictors of outcomes of the
transition from intravenous to
subcutaneous insulin
The transition to subcutaneous insulin
was successful (half or more of all ﬁrst-
day BG values in the strict ranges of 100–
140 mg/dL before meals and 100–180
after meals) in 75 patients (52.8%) and
unsuccessful in 67 patients (47.2%). Var-
iables associated with unsuccessful tran-
sition by multivariate analysis were old
age ($72 years, OR 2.292, 95% CI
1.082–4.856),highmeandose of intrave-
nousinsulininfusedinthe24hpreceding
the transition ($1.6 units/h, OR 2.202,
95% CI 1.045–4.640), and wide BG co-
efﬁcientofvariationinthe24hpreceding




The model of transition from intravenous
to subcutaneous insulin therapy used in
this study achieved from the ﬁrst day
approximately half of BG values within
thestrictrangesof100–140mg/dLbefore
meals and 100–180 after meals. The data
refertoapopulationalmostentirelymade
up of patients with a history of diabetes
admitted to an ICCU for an ACS. The
protocol gives the whole daily insulin re-
quirement,calculatedfromtheintravenous
insulin dose infused during the last 12 h,
administered as a basal-bolus in combina-
tion with regular oral feeding. Other pub-
lishedprotocolscalculatethesubcutaneous
insulin dose to be given the ﬁrst day after
transition on the basis of shorter reference
intravenousinfusionperiods(6–8h)andat
ﬁrst usually give only basal subcutaneous
insulin (generally 80% of the projected
24-h requirement calculated on the basis
of the insulin intravenous infusion rate),
adding rapid-acting insulin when the pa-
tients begin toeat(7,8,15).However,these
protocolshaveusually beensetfor patients
postsurgery who are eating little and have
been used indifferent clinical settings (sur-
gicalintensivecareunitsorsurgicaldepart-
ments) (7,8,15).
In 2006, Schmeltz et al. (11) pub-
lished the only randomized clinical trial
to our knowledge to determine the opti-
mal dose of insulin for the transition. The
patients were mostly nondiabetic, had re-
cently undergone operation, and were
taking little food if any. A dose of insulin
glargine corresponding to 80% of the to-
tal daily requirement, calculated on the
basis of the last 6-h intravenous infusion,
tended to achieve a better glycemic con-
trol in the ﬁrst 24 h in comparison with
conversion at 40 and 60%, with average
BG (before every meal and at bedtime) of
153.2 6 66.2 mg/dL and 48% of target
BG between 80 and 140 mg/dL.
Our data on the control of BG in the
ﬁrst days of subcutaneous insulin therapy
are comparable to those observed during
the whole hospital stay in the two major
trialsonthebasal-bolusinsulintherapyin
inpatients with diabetes. In the Random-
izedStudy ofBasal-Bolus InsulinTherapy
in the Inpatient Management of Patients
With Type 2 Diabetes (RABBIT 2) trial on
patients admitted to general medical
wards, mean BG values (fasting, premeal,
and at bedtime) were 166 6 32 mg/dL in
subjects randomized to receive glargine
and glulisine, and 66% of these patients
had mean BG ,140 mg/dL (17). In the
RABBIT 2 Surgery trial ongeneral surgery
patients, the mean daily BG was 157632
mg/dL in subjects randomized to glargine
and glulisine and the proportion of BG val-
ues ,140 mg/dL was 53 6 30% (18).
Safety
With our transition protocol, hypoglyce-
mic episodes occurred in approximately
one quarter of patients on the ﬁrst 3 days
of subcutaneous therapy, a rate similar to
Figure 1—BG concentrations (mean 6 SD) in the last 24 h of intravenous insulin infusion and
before and 2 h after breakfast, lunch, and dinner on the ﬁrst 3 days of subcutaneous insulin.
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Intravenous to subcutaneous insulinthat observed in other studies. In the
Schmeltzet al.trial(11),patientsenrolled
in the arm with the best transition from
intravenous to subcutaneous insulin had
4%ofBG#70mg/dLamongallmeasure-
ments on the ﬁrst day. In the observa-
t i o n a ls t u d yb yC z o s n o w s k ie ta l .( 9 ) ,
8% of patients had at least one hypogly-
cemic event (deﬁned as BG ,60 mg/dL)
the ﬁrst day after interruption of intrave-
nous insulin, whereas in the study by
Weant et al. (10) 8 hypoglycemic events
(deﬁned as BG ,80 mg/dL) occurred in
theﬁrst48haftertransitionin19patients
with diabetes and 13 hypoglycemic
events occurred in 60 patients without
diabetes.
Safety data in our population com-
pare well with those observed in the two
main trials on the basal-bolus insulin
therapy in hospitalized patients with di-
abetes: in the RABBIT 2 trial, 2 of 65
patients (3.1%) had BG ,60 mg/dL
before meals or at bedtime (17); in the
RABBIT 2 Surgery trial, 23.1 and 3.8%
of patients had BG ,70 and ,40 mg/dL,
respectively (18). When our protocol
was ﬁrst used, hypoglycemia was not a
major concern, but the safety issue is
now considered important because severe
hypoglycemia in critically ill patients, par-
ticularly in ACS, is associated with a
worse prognosis (19–21). In addition, re-
cent trials have found neutral or even neg-
ative results, with a signiﬁcant excess of
hypoglycemicevents,withmoreaggressive
treatment in critically ill patients (22–
24) and diabetic outpatients (25). Even if
all the hypoglycemic episodes in our pop-
ulation were asymptomatic and with no
immediate manifest clinical consequen-
ces, the patients with hypoglycemic epi-
sodes had a higher incidence of major
cardiovascular complications than those
without. Until proven otherwise, hypo-
glycemia should be considered a possible
cause for the increase in cardiac events
and every effort to prevent hypoglycemia
should be made in patients with ACS, in-
cluding the adoption of higher glucose
targets (2–4).
Predictors of a successful transition
In our population, the variables predic-
tiveofanunsuccessfultransitionwereold
age, high doses of intravenous insulin,
and wide BG variations in the 24 h before
insulin infusion was stopped. These var-
iables are all indicative of diabetes that is
difﬁcult to control.
Few studies have been published on
the predictors of optimal transition, and
most refer to patients different from ours,
often nondiabetic, recently surgically op-
erated, and with little or no food intake
(7,9,10). In these patients, in addition to
the complexity of the surgical interven-
tion and the presence of other clinical
complications, the variables predictive of
unsuccessful control of BG after the tran-
sition to subcutaneous insulin were poor
glycemic control during intravenous in-
sulin, high doses of intravenous insulin
required to control BG, high subcutane-
ous insulin doses, and history of diabetes,
especially type 1.
Feasibility
Despite the complexity of the transition
process that demands various nursing
and medical specialties (choosing the
best time to stop intravenous insulin;
formulating and planning basal, prandial,
and correction insulin doses; shifting
from intravenous feeding to an oral diet
calibrated to meet the patient’s needs;
performing frequent blood sampling for
bedside BG monitoring before and 2
hoursaftermeals)andthelogisticdifﬁcul-
ties arising from the frequent overlap of
these interventions when the patient is
moved from the ICCU to the general
ward, this study shows that the protocol
is feasible for medical and nursing staff.
During the transition from intrave-
nous to subcutaneous insulin, errors in
theapplication of the protocolwere made
in 16% of patients, generally as a conse-
quence of wrong calculation of the sub-
cutaneous dose. To limit this risk, a
computer program is now available to
make application of the protocol simpler
and more precise, and consequently to
improve its effectiveness and safety.
Study limits
The main limit of this study lies in the
peculiarity of the population and setting,
which may not allow extrapolation of the
results to patients with conditions other
thanACSandsettingswithorganizational
differences from an ICCU/cardiology
ward. The majority of our population
were known patients with diabetes, and
the results will not necessarily apply to
patients who do not have diabetes. Nev-
ertheless,webelievethemodeloftheACS
is representative enough of diabetic pa-
tients admitted to a medical ICU, and our
ﬁndings could help ﬁll the gap in the
literature where data on the transition
fromintravenoustosubcutaneousinsulin
mainly refer to surgical settings.
The current study shows the effec-
tiveness and safety of a standardized pro-
tocol for the transition from intravenous
to subcutaneous insulin in patients with
ACS at the moment of their transfer from
theICCUtoageneral ward.Thisprotocol
can already achieve optimal glycemic
control on the ﬁrst day in approximately
half the pre- and postprandial BG values,
witharateofhypoglycemiceventssimilar
tothatobtainedwithotherprotocols.The
variables predictive of unsuccessful tran-
sition were old age, high doses of in-
travenous insulin,and wideBGvariations
in the 24 h preceding the switch from
intravenous to subcutaneous insulin.
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APPENDIX—The DDD Study Group:
1) Medical staff of the Division of Cardi-
ology/ICCU: M. De Martini, A. Alberzoni,
F. Avanzini, G. Balestri, P. Bertocchi,
P. Camisasca, W. Donzelli, G. Iacuitti,
G. Mantovani, M. Mistò, E. Planca,
G. Pozzoli, R. Rogatska, D. Saltafossi,
S. Tresoldi, P. Vandoni. 2) Nursing staff
of the Division of Cardiology/ICCU:
S.Tomasello,R.Amodeo,S.Baldo,M.Berizzi,
J .B e r t a z z o l o ,S .B o t t a n ,G .B u s i ,S .C a r b o n e ,
M. Caspani, L. Ciotta, A. Colaianni, R. Cotza,
A. De Ponti, E. Di Rocco, V. Donè,
G .F e r o l e t o ,A . M .G a g l i a r d i ,M .K l a j n ,
M.Ilardi,A.Ledda,R.Mamo,M.Mancuso,
M. Mulieri, F. Orsenigo, E. Palazzo,
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